Selegiline — An overview of its role in the treatment of Parkinson's disease
Identifieur interne : 002613 ( Main/Exploration ); précédent : 002612; suivant : 002614Selegiline — An overview of its role in the treatment of Parkinson's disease
Auteurs : K. Wessel [Allemagne] ; I. SzelenyiSource :
- The clinical investigator [ 0941-0198 ] ; 1992-05-01.
Abstract
Summary: Selegiline (10 mg per day) selectively inhibits monoamine oxidase type B and thus thwarts the metabolism of dopamine by this enzyme. Selegiline has been used in the therapy of Parkinson's disease since 1986. It enhances the efficacy of levodopa, allows a reduction of the levodopa dose, and improves fluctuations in disability. It also interacts with mechanisms suspected of playing a role in the progression of the disease. Animal studies have shown that selegiline prevents the development of a Parkinson-like syndrome induced by the neurotoxin MPTP. It decreases oxidative stress resulting from the metabolism of dopamine via MAO-B. Clinical studies have shown that selegiline is effective in the therapy of untreated de novo patients the progression of symptoms demanding the introduction of levodopa into the therapy was delayed, and the risk of needing levodopa treatment within one year was reduced by 57% with selegiline. The mode of action of this drug in the treatment of early Parkinson's disease is still under discussion. There is strong evidence that selegiline may slow the progression of the disease, but a direct symptomatic effect cannot be excluded.
Url:
DOI: 10.1007/BF00235534
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selegiline — An overview of its role in the treatment of Parkinson's disease</title><author><name sortKey="Wessel, K" sort="Wessel, K" uniqKey="Wessel K" first="K." last="Wessel">K. Wessel</name></author><author><name sortKey="Szelenyi, I" sort="Szelenyi, I" uniqKey="Szelenyi I" first="I." last="Szelenyi">I. Szelenyi</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:03C2A0AC7CFD052CA2BB5DEE1A426AC05F846D37</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1007/BF00235534</idno><idno type="url">https://api.istex.fr/document/03C2A0AC7CFD052CA2BB5DEE1A426AC05F846D37/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000F91</idno><idno type="wicri:Area/Main/Curation">000E07</idno><idno type="wicri:Area/Main/Exploration">002613</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Selegiline — An overview of its role in the treatment of Parkinson's disease</title><author><name sortKey="Wessel, K" sort="Wessel, K" uniqKey="Wessel K" first="K." last="Wessel">K. Wessel</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>ASTA Medica AG, Weismüllerstrasse 45, W-6000, Frankfurt/Main 1</wicri:regionArea><wicri:noRegion>Frankfurt/Main 1</wicri:noRegion><wicri:noRegion>Frankfurt/Main 1</wicri:noRegion></affiliation></author><author><name sortKey="Szelenyi, I" sort="Szelenyi, I" uniqKey="Szelenyi I" first="I." last="Szelenyi">I. Szelenyi</name><affiliation><wicri:noCountry code="subField">Frankfurt/Main</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">The clinical investigator</title><title level="j" type="abbrev">Clin Investig</title><idno type="ISSN">0941-0198</idno><idno type="eISSN">1432-1440</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1992-05-01">1992-05-01</date><biblScope unit="volume">70</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="459">459</biblScope><biblScope unit="page" to="462">462</biblScope></imprint><idno type="ISSN">0941-0198</idno></series><idno type="istex">03C2A0AC7CFD052CA2BB5DEE1A426AC05F846D37</idno><idno type="DOI">10.1007/BF00235534</idno><idno type="ArticleID">Art19</idno><idno type="ArticleID">BF00235534</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0941-0198</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Selegiline (10 mg per day) selectively inhibits monoamine oxidase type B and thus thwarts the metabolism of dopamine by this enzyme. Selegiline has been used in the therapy of Parkinson's disease since 1986. It enhances the efficacy of levodopa, allows a reduction of the levodopa dose, and improves fluctuations in disability. It also interacts with mechanisms suspected of playing a role in the progression of the disease. Animal studies have shown that selegiline prevents the development of a Parkinson-like syndrome induced by the neurotoxin MPTP. It decreases oxidative stress resulting from the metabolism of dopamine via MAO-B. Clinical studies have shown that selegiline is effective in the therapy of untreated de novo patients the progression of symptoms demanding the introduction of levodopa into the therapy was delayed, and the risk of needing levodopa treatment within one year was reduced by 57% with selegiline. The mode of action of this drug in the treatment of early Parkinson's disease is still under discussion. There is strong evidence that selegiline may slow the progression of the disease, but a direct symptomatic effect cannot be excluded.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Szelenyi, I" sort="Szelenyi, I" uniqKey="Szelenyi I" first="I." last="Szelenyi">I. Szelenyi</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Wessel, K" sort="Wessel, K" uniqKey="Wessel K" first="K." last="Wessel">K. Wessel</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002613 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002613 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:03C2A0AC7CFD052CA2BB5DEE1A426AC05F846D37
|texte= Selegiline — An overview of its role in the treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |